Trial Profile
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms HEAT
- Sponsors Celsion Corporation; Imunon
- 19 Sep 2022 According to an Imunon media release, Celsion Corporation changed it's name to Imunon.
- 04 Feb 2020 Results published in the Celsion Corporation Media Release
- 04 Feb 2020 Acccording to a Celsion Corporation Media Release, data from this study was presented at the SPECTRUM 2020 Interventional Oncology Conference.